Fill in the form below to subscribe to the ActoGeniX newsletter.
ActoGeniX completes manufacturing of its clinical product AG011 and prepares for phase 2 clinical trial
ActoGeniX expands its management team and appoints Anders Waas as Vice President Business Development
ActoGeniX receives EUR 3 million from the Flanders government through IWT.